16 岁的 Jonathan Lubin 患有镰状细胞病，接受了实验性 CRISPR 基因编辑疗法，减少了疼痛危机和住院治疗。 16-year-old Jonathan Lubin, with sickle cell disease, underwent experimental CRISPR gene editing therapy, reducing pain crises and hospitalizations.
16 岁的乔纳森·卢宾 (Jonathan Lubin) 是一名镰状细胞病患者，他在纽约长老会/哥伦比亚医院接受了实验性 CRISPR 基因编辑治疗。 Sixteen-year-old Jonathan Lubin is a sickle cell disease patient who received experimental CRISPR gene editing therapy at New York-Presbyterian/Columbia. 治疗需要化疗，并涉及收获、编辑和重新引入他自己的干细胞的复杂过程。 The treatment required chemotherapy and involved the complex process of harvesting, editing, and reintroducing his own stem cells. 如今，卢宾已经两年多没有经历过疼痛危机或住院治疗，这与他以前经常去医院的生活形成了鲜明的对比。 Today, Lubin has not experienced a pain crisis or hospitalization for over two years, reflecting a stark contrast to his previous life filled with frequent hospital visits.